BlackRock Inc. boosted its position in shares of Cytosorbents Corp (NASDAQ:CTSO) by 1.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,008,123 shares of the medical research company’s stock after acquiring an additional 21,791 shares during the quarter. BlackRock Inc. owned 6.22% of Cytosorbents worth $13,274,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Skylands Capital LLC lifted its position in Cytosorbents by 7.0% during the second quarter. Skylands Capital LLC now owns 680,600 shares of the medical research company’s stock worth $4,499,000 after purchasing an additional 44,550 shares during the period. Northern Trust Corp lifted its position in Cytosorbents by 1.7% during the second quarter. Northern Trust Corp now owns 354,447 shares of the medical research company’s stock worth $2,343,000 after purchasing an additional 5,852 shares during the period. Sargent Investment Group LLC lifted its position in Cytosorbents by 15.9% during the second quarter. Sargent Investment Group LLC now owns 333,910 shares of the medical research company’s stock worth $2,207,000 after purchasing an additional 45,840 shares during the period. Avenir Corp lifted its position in Cytosorbents by 66.6% during the second quarter. Avenir Corp now owns 145,300 shares of the medical research company’s stock worth $960,000 after purchasing an additional 58,060 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Cytosorbents by 31.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 81,270 shares of the medical research company’s stock worth $538,000 after purchasing an additional 19,439 shares during the period. 26.45% of the stock is currently owned by hedge funds and other institutional investors.
In other Cytosorbents news, CFO Kathleen P. Bloch purchased 6,500 shares of the stock in a transaction dated Friday, August 16th. The shares were purchased at an average cost of $4.83 per share, with a total value of $31,395.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 5.60% of the company’s stock.
NASDAQ:CTSO traded up $0.11 on Friday, reaching $4.61. 160,400 shares of the stock traded hands, compared to its average volume of 147,829. The firm has a market capitalization of $163.78 million, a price-to-earnings ratio of -8.23 and a beta of 1.68. The company’s 50 day moving average is $4.88 and its 200-day moving average is $5.92. Cytosorbents Corp has a 1-year low of $3.68 and a 1-year high of $11.20. The company has a current ratio of 3.21, a quick ratio of 3.00 and a debt-to-equity ratio of 0.87.
Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.08). The firm had revenue of $6.10 million during the quarter, compared to analysts’ expectations of $6.49 million. Cytosorbents had a negative return on equity of 142.91% and a negative net margin of 87.79%. On average, equities research analysts forecast that Cytosorbents Corp will post -0.53 EPS for the current fiscal year.
A number of research analysts have recently commented on CTSO shares. ValuEngine cut shares of Cytosorbents from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Maxim Group set a $14.00 target price on shares of Cytosorbents and gave the stock a “buy” rating in a report on Wednesday, August 7th. B. Riley set a $10.00 target price on shares of Cytosorbents and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, HC Wainwright reiterated a “buy” rating on shares of Cytosorbents in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Cytosorbents currently has a consensus rating of “Hold” and an average target price of $13.00.
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Recommended Story: Return on Equity (ROE)
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.